|
대식세포 이동저해인자(글리코실화 억제인자, L-Dopachrome Isomerase, MIF, EC 5.3.2.1) : 파이프라인 리뷰
Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019
|
| 리서치사 |
Global Markets Direct
|
| 발행일 |
2019년 12월 |
상품 코드 |
358689 |
| 페이지 정보 |
영문 50 Pages |
| 가격 |
|
|
대식세포 이동저해인자(글리코실화 억제인자, L-Dopachrome Isomerase, MIF, EC 5.3.2.1) : 파이프라인 리뷰
Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019
|
| 발행일 : 2019년 12월 | 페이지 정보 : 영문 50 Pages |
|
|
※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.
대식세포 이동저해인자(MIF)는 글리코실화 억제인자(GIF)로도 알려져 있으며, MIF 유전자에 의해 코딩되는 단백질입니다. MIF는 중요한 선천성 면역 조절인자입니다.
대식세포 이동저해인자(글리코실화 억제인자, L-Dopachrome Isomerase, MIF, EC 5.3.2.1) 개발 상황을 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.
목차
서론
개요
치료제 개발
- 개발중인 제품 : 개발 단계별
- 개발중인 제품 : 치료 분야별
- 개발중인 제품 : 적응별
파이프라인 제품 개요
개발중인 제품 : 기업별
치료제 평가
- 단됵요법/병용요법별
- 작용기전별
- 투여 경로별
- 분자 종류별
치료제 개발에 참여하고 있는 기업
- Baxalta Incorporated
- Kyorin Pharmaceutical Co., Ltd.
약제 개요
휴지 상태인 프로젝트
최신 뉴스와 프레스 릴리스
부록
도표
LSH 16.07.19
List of Tables
- Number of Products under Development by Stage of Development, H2 2019
- Number of Products under Development by Therapy Areas, H2 2019
- Number of Products under Development by Indications, H2 2019
- Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
- Number of Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019 (Contd..1), H2 2019
- Number of Products under Investigation by Universities/Institutes, H2 2019
- Products under Investigation by Universities/Institutes, H2 2019
- Number of Products by Stage and Mechanism of Actions, H2 2019
- Number of Products by Stage and Route of Administration, H2 2019
- Number of Products by Stage and Molecule Type, H2 2019
- Pipeline by Apaxen, H2 2019
- Pipeline by GlaxoSmithKline Plc, H2 2019
- Pipeline by Ibex Biosciences LLC, H2 2019
- Pipeline by Innovimmune Biotherapeutics Inc, H2 2019
- Pipeline by L2 Diagnostics LLC, H2 2019
- Pipeline by Mifcare, H2 2019
- Pipeline by MIFCOR Inc, H2 2019
- Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
- Dormant Products, H2 2019
- Dormant Products, H2 2019 (Contd..1), H2 2019
- Discontinued Products, H2 2019
List of Figures
- Number of Products under Development by Stage of Development, H2 2019
- Number of Products under Development by Therapy Areas, H2 2019
- Number of Products under Development by Top 10 Indications, H2 2019
- Number of Products by Mechanism of Actions, H2 2019
- Number of Products by Stage and Mechanism of Actions, H2 2019
- Number of Products by Stage and Route of Administration, H2 2019
- Number of Products by Molecule Types, H2 2019
- Number of Products by Stage and Molecule Types, H2 2019
Summary
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019, outlays comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor (GIF) is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells (DC) and T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF-α, nitric oxide and cyclooxygenase 2 (COX-2). MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to release MIF into the blood stream. The circulating MIF binds to CD74 on other immune cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoid. The molecules developed by companies in Preclinical and Discovery stages are 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Respiratory, Dermatology and Infectious Disease which include indications Rheumatoid Arthritis, Glomerulonephritis, Inflammatory Bowel Disease, Multiple Sclerosis, Pulmonary Arterial Hypertension, Type 1 Diabetes (Juvenile Diabetes), Alzheimer's Disease, Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Crohn's Disease (Regional Enteritis), Idiopathic Pulmonary Fibrosis, Inflammation, Malaria, Myocardial Infarction, Obesity, Prostate Cancer, Psoriasis, Systemic Lupus Erythematosus, Type 2 Diabetes and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)
- The report reviews Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Overview
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Companies Involved in Therapeutics Development
- Apaxen
- GlaxoSmithKline Plc
- Ibex Biosciences LLC
- Innovimmune Biotherapeutics Inc
- L2 Diagnostics LLC
- Mifcare
- MIFCOR Inc
- Takeda Pharmaceutical Co Ltd
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Drug Profiles
- BaxB-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BaxG-03 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INV-88 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- malaria vaccine 1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MFC-1040 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MFC-2040 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MIF-20 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibodies to Inhibits MIF for Prostate Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- P-425 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule to Inhibit MIF for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit MIF for Autoimmune Disorders and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit MIF for Inflammatory Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit MIF for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Dormant Products
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Discontinued Products
- Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) - Product Development Milestones
- Featured News & Press Releases
- Jul 13, 2018: Yale researchers identify target for novel malaria vaccine
- Jan 10, 2017: Abzyme receives Milestone Payment from Ibex for Anti-cancer VHH Antibodies
- Sep 09, 2016: Mifcare Announces Positive Preclinical Efficacy Data for MFC1040 in Sugen/Chronic Hypoxia Model of Severe Pulmonary Arterial Hypertension
- Jul 15, 2016: Mifcare Announces Positive Preclinical Results with MFC1040 in Pulmonary Arterial Hypertension
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
|
 |
|
